Targeted therapies in lung cancer.

  title={Targeted therapies in lung cancer.},
  author={Robert Pirker and Martin Filipits},
  journal={Current pharmaceutical design},
  volume={15 2},
Targeted therapies have improved and will continue to improve the outcome of lung cancer. Current strategies focus on the blockade of growth factor receptors and the inhibition of angiogenesis. Epidermal growth factor receptor (EGFR)-directed tyrosine kinase inhibitors (TKIs) have already been established as a treatment option in patients with advanced non… CONTINUE READING